Btg Share Discussion Threads

[waterloo01] 13/6/2017 20:18

All part of the defence of Crofab. They need to differentiate it if they want to maintain the premium price, although they are still likely to see pricing pressure. Any rumour of Abiraterone patent extension would be significant, so need to keep an eye on that as it's a 'work in progress' re generics.

[aphrodites] 13/6/2017 20:01

fhmktg

You should breath in again and wait for news possibly on the 15th which could be very important for the share price.

And as for Crofab why not update everyone with the news released today, not massive but nevertheless interesting and was not the reason for today's price rise???????????

New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation

PHILADELPHIA, June 13, 2017 /PRNewswire/ --

A study sponsored by BTG plc (LSE: BTG), the global specialist healthcare company, has been recently published in the Annals of Emergency Medicine (AEM) that shows administering CroFab® to patients envenomated by copperhead snakes can aid the recovery of a patient's affected limb function as compared with placebo.

(Logo: hxxp://photos.prnewswire.com/prnh/20150805/255981LOGO )
The randomised, double-blind, placebo-controlled study compared CroFab® Crotalidae Polyvalent Immune Fab (Ovine) - the only antivenom currently marketed for the treatment of crotaline snake envenomation - against placebo for the treatment of copperhead snake envenomation for the first time.

Copperhead envenomation is generally considered less severe than other North American Pit Viper snakebites, but more than 95% of copperhead victims still develop significant pain and swelling of the injured limb, and other soft tissue injury. Most patients resume activities within 2-4 weeks but residual symptoms can last for a year.

Dr Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in Copperhead snake envenomation, said: "For the first time, this data demonstrates that CroFab® improves recovery of limb function from Copperhead envenomation. Additionally, antivenom treatment was associated with less opioids use throughout the patient's recovery. These results can be used to help physicians and patients make a more informed choice about their care."

In total, 74 patients participated in the study; 45 were treated with CroFab® and the rest received a placebo. All participating trial staff (apart from the study pharmacist) and patients were unaware of the treatment given in each case. Within the patient cohort was a mix of upper and lower extremity conditions depending on where the copperhead had bitten the patient.

The Patient Specific Functional Scale (PSFS) was used to measure study outcomes by assessing each patient's ability to do daily activities that they were unable to do or had difficulty with post copperhead inflicted injury. The tasks varied from driving a car, climbing the stairs, brushing teeth, or using a cell phone and took in to account the score at envenomation + 14 days using a 0-10 scale. In addition to the positive primary outcome of the study, it was also discovered that opioid analgesic use was less in CroFab® treated patients.

Dan Schneider, SVP and General Manager, Specialty Pharmaceuticals, Commercial Operations at BTG, said: "We are pleased with the clinical study findings that show that patients treated with CroFab® recover faster from Copperhead bites. Even though we haven't reached summer months yet, we are seeing multiple reports stating that the frequency of bites in the U.S. are on the rise this year. As snake sightings start to pick up, don't forget to download our free, educational SnakeBite911™ App Suite. It has useful information about the dos and don'ts if envenomation occurs and helps raise awareness about North American Pit Vipers."

To review the published article in full, please refer to the following link: hxxp://www.annemergmed.com/article/S0196-0644(17)30510-3/fulltext.

Indication

CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

Important Safety Information

The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.


For further information contact:

BTG
Andy Burrows, VP Corporate & Investor Relations

[bargainbob] 13/6/2017 17:23

Where fhmktg ?

[fhmktg] 13/6/2017 13:48

I can breathe out now!Good news for the old favourite Crofab!

[fhmktg] 13/6/2017 11:22

Having pushed......now hold your breath!

[charlock] 13/6/2017 10:55

That worked... Well done!

[fhmktg] 13/6/2017 09:39

Aaaaand, PUSH!

[bargainbob] 12/6/2017 17:32

May will be in power until the AGM

[fhmktg] 12/6/2017 17:17

Just over a month to go for the agm statement.For goodness sakes, let's have something to cheer us up!

[dp1umb] 05/6/2017 14:47

A US doctor has commented that the zytiga results will change prostate treatment protocol overnight.

[dr biotech] 05/6/2017 12:28

It will take time to get the label extended for earlier use. Also it may not be that beneficial in the worlds largest market the US as they spend a lot more on screening and the percentages of cancers caught late is much smaller than elsewhere.

Still positive news, but perhaps not a huge financial boost for btg.

[bargainbob] 05/6/2017 12:19

Interested in your thoughts too Aprrodities , news around January about codes was my biggest expectation for a positive upswing .

Though would not be surprised of another 250-400 million bolt on to BTG in the coming months .

[fhmktg] 05/6/2017 11:22

Aphrodites, what are you expecting?

[fhmktg] 05/6/2017 11:21

Dp1umb, it looks very complicated!Currently in court with the target to delay generics until 2027.Let's hope they succeed

[bscuit] 05/6/2017 11:04

Last week's rise was obviously as the newspapers and the MMs knew what would be publicly released later.

[dp1umb] 05/6/2017 10:52

The zytiga news will feed through to higher revenues this year even maybe offsetting the loss of Lemtrada sales, but does any one actually know BTGs position with the patient expires concerning Zytiga?( Iam totally confused is it 2018 or 2027?)

[aphrodites] 05/6/2017 09:26

Not fake news dp1umb but too many had the same idea!

If the price had hit £7 I would have sold on the spike up in the hope to buy back lower down.

I do not believe the cancer news is what the insiders are looking for.

There is more important news to come in the next 4 weeks and I believe when today's hype calms down the share price will continue its upwards path.

[dp1umb] 05/6/2017 09:12

Fake news?

[davr0s] 05/6/2017 08:33

Fake news? Trying to make a new story out of this when there isn't one. You'd have thought cancer had been cured reading it lol

[fhmktg] 05/6/2017 08:25

Guess it was priced in!

[waterloo01] 05/6/2017 08:16

Back in again this AM. I certainly wasn't aware of the latest trial, but a little out of touch.

[davr0s] 05/6/2017 08:11

Nothing to see here then - looks like market already aware?

[bargainbob] 05/6/2017 07:32

More shop window for BTG may cause a few to a sniff , 25 p hope your right .